Decision making for patients with complex feeding issues have previously been made in isolation. It is advocated for cohesive decisions to be made in a multidisciplinary setting.1 Since the 2013 appointment of a nurse specialist, complex feeding decisions are made in our tertiary MDT complex enteral feeding (CEN) clinic. We aim to describe clinical outcomes with reference to changes in medical and surgical therapies. From a prospectively gathered departmental database, all patients reviewed in CEN clinic (03/2013–12/2022) were assessed for: demographics; primary diagnosis; referral mode. Interventions of interest: fundoplication; jejunal feeding; blenderised diet (BD). Patients commenced on jejunal feeding or BD each year were calculated. Comparison of proportionate interventions for when dietetic support for BD was and was not resourced was performed by fisher’s exact test (sig p≤0.05). Of 201 patients reviewed: 61% had a severe neurodisability; 26% multisystem disease; 7% complex GI surgery; 4% complex cardiology; 2% isolated complex feeding issue. 62% male, median age at referral was 3.3 years. 58 fundoplications were performed, 99 received jejunal feeding (initiated with 37 nasojejunal; 58 gastrojejunal device; 4 surgical jejunostomy) and 57 patients of the 72 recommended started BD. BD has been advocated by team since 2016 as a feeding strategy for gastric intolerance of milk formula. Dietetic support to establish BD was resourced 2018–2020. Out-with this timeframe, availability was limited in certain areas. After rising incident cases of jejunal feeding, we observed a reduction with the introduction of dietetic resource to support BD initiation (2018–2020). This trend was reversed 2021–2022 with significantly higher jejunal initiation being required (p=0.0005) (figure 1). We observe a reduction in fundoplication from 11 to 3 per year, in line with increased in jejunal feeding and BD. A small minority required a period of parenteral nutrition (PN) support including 2 patients who received PN for > 12 months. We report the longitudinal trends in intervention in a CEN clinic with reduction of fundoplication and rise then reduction in jejunal feeding when dietetic support for BD was available. The reduction in BD initiation 2021–2022 sits chronologically with the withdrawal of dietetic support and resulted in significant rise in jejunal feeding. We highlight the success of fundoplication for patients in our service with careful selection. This has driven service redesign within our institution. Jejunal feeding has become secondary to a trial of BD in our hierarchy due to BD benefits including: less invasive feeding modality; apparent better symptom control; parental wishes and cost saving. Effects of the pandemic and dietetic resource may have restricted access to BD in the last 2 years. Reference Broekaert IJ, Falconer J, et al. JPGN. 2019 Aug;69(2):239–258.
The role of lipid manipulations in parenteral nutrition (PN) in changing the natural history of IFALD is well established. European centres report utilising a mixed lipid formula ‘SMOF’ (Soy, Medium chain (coconut), Olive and Fish) for prevention and treatment of IFALD, with North American centres using a pure fish oil ‘Omegaven’ in established IFALD.1Whilst there has been a suggestion that the use of Omegaven may have additional benefit for ‘rescue therapy’ for patients on SMOF lipid who have still developed IFALD.2 either with cholestasis or deterioration of LFTs, to date there are limited published ‘real world’ cross-over data. We report our use of Omegaven rescue therapy (ORT) in paediatric Intestinal Failure (IF). Since Jan 2019, under the advice of the specialist nutrition team, ORT was used selectively in the apriori agreed context of: IF, continued evidence of worsening liver function (total bilirubin (Tbil) >20umol/l or x3 rise in ALT/AST) despite anti-sepsis measures and prior lipid reduction to 1g/kg/day. Omegaven was given at 1–1.5g/kg/day. Data from Jan 2019- Dec 2022 was gathered including: demographics, sepsis, serial change in Tbil, Conjugated bilirubin, AST/ALT, with trend analyses over multiple time points with date of commencement ORT was performed using Dunnett multiple comparisons with control (CI 95% p<0.05). Exclusions to analyses included: inadequate rise in LFTs/Tbil, death during Rx and additional liver diagnoses. 15 included patients (8 in NICU) received ORT. ORT was given for 7–33 days. Median Tbil levels were rising significantly prior to ORT and then fell significantly both at T+14 days and T+28 days. (Figure 1). ALT/AST fell in the group but was not statistically significant. Including retreatments in individual patients also reduced treatment effect. We present provisional data of ORT in patients already established on SMOF and lipid lowering strategies. We see that the most common indication for Omegaven is rising liver function tests both in context of sepsis/suspected sepsis and longstanding IFALD. We observed a rapid significant fall in Tbil with 14 days of therapy, despite a significantly rising Tbil prior to initiation. These data could be improved by additional cases, and defining a contemporary control group that are well matched for IF co-morbidity, age and deteriorating liver function however they differ to the natural history of IFALD. The possibility for a more sustained switch to Omegaven in a very select group of IF patients with longstanding deteriorating liver function merits exploration, as does the use of ORT in IF patients at risk of liver dysfunction during sepsis episodes. Tbil levels in 15 patients prior to and after initiating ORT (Median in bold) References Barclay AR, Henderson P. J Pediatr Gastroenterol Nutr 2016;62(3):363–4. ESPGHAN; Lapillonme A, et al. Clin Nutr 2018;37:2324–36.
The complex and progressive debilitating symptoms associated with severe neurodisability and the gastrointestinal tract have long been recognised by specialist nutrition support teams, however have only recently been characterised as GID.1 Whether progressive disease represents specific GI dysfunction or heralds global decline in patient health is poorly defined. Insights into longitudinal treatment success, disease progression, morbidity and mortality would help inform complex decision making for professionals and carers looking after patients with life limiting conditions. We describe outcomes for patients meeting agreed criteria of GID in a tertiary specialist complex feeding (CEN) service. Patients prospectively gathered on departmental database were identified from referrals 03/2013–12/2020 (entry criteria being ≥2 yrs follow up) and were assessed for: baseline demographics; medications used; surgical interventions; blenderised diet (BD); jejunal feeding; parenteral nutrition (PN) episodes; mortality. Patient notes were independently reviewed by 2 authors to agree if they fulfilled criteria for GID, with a third author adjudicating if discordant. 163 patients were referred to the CEN team over the timeline with 40 fulfilling GID. Median age 5.3 years. Diagnosis included: 80% cerebral palsy; 12% genetic syndrome associated with neurodisability; 8% epileptic encephalopathy. 53% had a fundoplication, 58% jejunal feeding and 73% BD over timeline. 85% had >3 medication at any time for GID symptoms (figure 1). Patients received 1–3 tone medications, 55% also had botox muscle injections and 18% intrathecal baclofen pump therapy. The majority also received multiple sedating and analgesic medications. There were 3 episodes of PN in 3 patients, with one patient being trained for home PN. One patient received PN in what became evidently a palliative phase. Overall mortality was 6 (15%) over 3 years from entry into CEN service. 3 deaths were from GID and 3 from other causes related to primary condition. Associated therapies included: 25% respiratory home ventilatory support; 35% spinal team assessment; 25% salivary gland botox or surgery. We present the first case series using defined criteria for GID. We describe the complexity, co-morbidity and disease burden of this condition. Polypharmacy is substantial and requires multi-speciality co-ordination of prescribing and monitoring to inform overall strategy. We would advocate symptom management plans led by palliative and supporting care colleagues. We highlight the resource implications and need for a co-ordinating case holder for these patients with complex multisystem needs. It is of note that the minority of patients benefited from PN for symptom control and went onto HPN. Mortality is significant from GID or co-morbidities in this population. Reference Barclay AR, Meade S, et al. Frontline Gastroenterology 2022;13:A9–A10.